[225Ac]Ac-FL-261 / Full-Life Technologies Limited - LARVOL DELTA

Phase 1/2 study of [225Ac]Ac-FL-261 in participants with c-MET-overexpressing solid tumors (chinadrugtrials.org.cn) - P1/2 | N=0 | Not yet recruiting | Sponsor: Full-Life Techinologies UK Limited / Shanghai Radiation Alliance Pharmaceutical Technology Co., Ltd. / AtomVie Global Radiopharma Inc.

First-in-human • New P1/2 trial • Oncology • Solid Tumor • MET